Guggenheim initiated coverage of Neurogene (NGNE) with a Buy rating and $69 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Expands Leadership Team to Drive NGN-401 Commercialization
- Neurogene appoints Christy Shafer as CCO
- Compelling Risk‑Reward in Neurogene’s NGN-401: Differentiated Gene Therapy Approach in Rett Syndrome Supports Buy Rating
- 3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
- Neurogene price target lowered to $180 from $200 at Canaccord